Galera Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Galera Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q2 2024.
  • Galera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$4.06M, a 80.4% increase year-over-year.
  • Galera Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$29.1M, a 58.8% increase year-over-year.
  • Galera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$59.1M, a 5.05% increase from 2022.
  • Galera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$62.2M, a 22.7% increase from 2021.
  • Galera Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$80.5M, a 8.51% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$29.1M -$4.06M +$16.6M +80.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$45.8M -$4.38M +$13.3M +75.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-14
Q4 2023 -$59.1M -$5.59M +$10.6M +65.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$69.7M -$15.1M +$960K +5.99% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$70.6M -$20.7M -$6.15M -42.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$64.5M -$17.7M -$2.27M -14.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-14
Q4 2022 -$62.2M -$16.2M +$619K +3.68% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$62.8M -$16M +$6.59M +29.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$69.4M -$14.6M +$7.83M +35% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$77.3M -$15.4M +$3.27M +17.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$80.5M -$16.8M +$3.26M +16.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-08
Q3 2021 -$83.8M -$22.6M -$5.55M -32.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$78.2M -$22.4M -$3.73M -20% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$74.5M -$18.7M -$298K -1.62% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$74.2M -$20.1M -$3.39M -20.4% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$70.8M -$17.1M -$3.73M -27.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$67.1M -$18.7M -$7.1M -61.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$60M -$18.4M -$8.07M -78% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$51.9M -$16.7M -$8.11M -94.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$43.8M -$13.4M -$8.1M -154% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$35.7M -$11.6M -$7.23M -167% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$28.5M -$10.3M -$4.82M -87% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
Q4 2018 -$23.7M -$8.56M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$5.25M Jul 1, 2018 Sep 30, 2018 10-Q 2019-12-10
Q2 2018 -$4.33M Apr 1, 2018 Jun 30, 2018 10-Q 2019-12-10
Q1 2018 -$5.53M Jan 1, 2018 Mar 31, 2018 10-Q 2019-12-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.